Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Aurobindo Pharma's Telangana Unit completes USFDA inspection
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Polepally Village, Jedcherla Mandal, Mahaboobnagar District, 509302, Telangana from 28 January to 10 February 2026. At the end of the inspection, a Form 483' was issued with a total of 9 observations.
Aurobindo Pharma shares gain after USFDA classifies Telangana facility as VAI
Aurobindo Pharma shares rise nearly 2% after USFDA issues Establishment Inspection Report, classifies Telangana Unit-VII as Voluntary Action Indicated, closing inspection.
Aurobindo Pharma to launch ₹800 crore buyback at ₹1,475 per share from April 23
Shares of Aurobindo Pharma Ltd ended at ₹1,387.05, up by ₹19.35, or 1.41%, on the BSE.
CLSA says Nifty has given a new signal on the charts; check potential returns and top midcap 'buys'
Laurence Balanco of CLSA has shared five midcap ideas: BSE, MCX, Apollo Tubes, Dixon Technologies and Aurobindo Pharma.
Buyback alert! Last date to buy Aurobindo Pharma shares for Rs 800-crore share buyback. Check details
Aurobindo Pharma has announced an ₹800-crore buyback at ₹1,475 per share, with April 17, 2026 set as the record date—meaning investors must buy shares before this date to be eligible.
Aurobindo Pharma arm expands MSD pact, to invest $150-175 million in new facility
As part of the arrangement, TheraNym will build the facility, manufacture the products, and supply them to MSD.
Aurobindo Pharma arm expands MSD pact, to set up $150-175 million facility
Aurobindo Pharma unit TheraNym expands CMO deal with MSD, to build 60,000 litre Unit 2 drug substance plant investing $150 to $175 million, stock gains 2.63%.
Share buybacks this month: Wipro, Aurobindo Pharma, 2 other stocks to watch out for
Four companies—Wipro, Cyient, Windlas Biotech, and Aurobindo Pharma—are set to announce or act on share buybacks this month, with Aurobindo’s record date due soon. Buybacks involve companies repurchasing shares to boost value, use surplus cash, or strengthen ownership. Meanwhile, new rules under the Finance Bill 2026 impose a 12% surcharge on buyback-related capital gains for promoters, while other investors remain taxed as per existing norms.
Aurobindo Pharma share buyback, Muthoot Fin dividend, 2 other corporate actions next week
Aurobindo Pharma’s share buyback and Muthoot Finance’s dividend announcement headline a set of four key corporate actions lined up for the coming week.
AstraZeneca India plans to sell 64-acre Bengaluru site for Rs 3,400 crore
The land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva Group, Aurobindo Pharma and RMZ. The company is looking to sell it as part of a broader land monetisation strategy.
Stocks to Watch Today: Infosys, Aurobindo Pharma, Swan Defence, Arvind SmartSpaces, Prostarm Info,... - Moneycontrol.com
Stocks to Watch Today: Infosys, Aurobindo Pharma, Swan Defence, Arvind SmartSpaces, Prostarm Info,...Moneycontrol.com
Aurobindo Pharma gets USFDA approval for diabetes drug
Aurobindo Pharma has received USFDA approval for Dapagliflozin and Metformin tablets used to treat Type-2 diabetes, with plans to launch the product immediately in the US market.